Freeline publishes preclinical proof-of-concept data for FLT190, its AAV gene therapy candidate for Fabry disease, in the Nature Journal Gene Therapy

Freeline Therapeutics has announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a debilitating genetic disorder in which an enzyme deficiency leads to a harmful build-up of fat in the cells that causes progressive organ damage and can result in early death.

Freeline is a clinical-stage biotechnology company developing transformative gene therapies for people with inherited systemic debilitating diseases. In 2020, they announced their IPO on Nasdaq which raised $158.8m.

Read more from Freeline here.